Actinogen boosts cash reserves with additional A$1.9m R&D tax rebate

The latest announcement is out from Actinogen Medical ( (AU:ACW) ).

Actinogen Medical has received a further A$1.87 million research and development tax incentive rebate from the Australian Tax Office, taking its total rebate for the 2025 financial year to A$7.36 million. The latest payment relates to overseas R&D expenditure that became eligible following approval under the Advanced Overseas Finding scheme.

The rebate strengthens Actinogen’s funding base as it nears key value inflection points in its Alzheimer’s disease program, including a phase 2b/3 trial of Xanamem that recently passed an independent safety and futility review. With topline results expected in November, the additional non-dilutive cash support is strategically important for sustaining clinical progress and may help the company maintain momentum in a competitive neurodegenerative drug development landscape.

The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical is an ASX-listed biotechnology company developing Xanamem, a first-in-class oral therapy targeting neurological and neuropsychiatric diseases linked to dysregulated brain cortisol, including Alzheimer’s disease and treatment-resistant depression. The company focuses on addressing substantial unmet medical needs in cognitive disorders, with late-stage clinical programs under way in Australia and the U.S. for Alzheimer’s and prior phase 2 data in depression supporting its cortisol-control mechanism.

Average Trading Volume: 6,135,532

Technical Sentiment Signal: Hold

Current Market Cap: A$137.3M

For detailed information about ACW stock, go to TipRanks’ Stock Analysis page.